Heart failure biomarkers at point-of-care: Current utilization and future potential

Expert Review of Molecular Diagnostics

Volumn 14, Issue 2, 2014, Pages 185-197

  Christenson, Eric S ^a   Collinson, Paul O ^b   Defilippi, Christopher R ^c   Christenson, Robert H ^c,d  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b ST GEORGE S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

amino terminal pro B type natriuretic peptide; B type natriuretic peptide; cardiac biomarkers; heart failure; point of care; troponin

Indexed keywords

AGED; BIOLOGICAL MARKERS; CARDIOLOGY; FEMALE; HEART FAILURE; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; NATRIURETIC PEPTIDE, C-TYPE; POINT-OF-CARE SYSTEMS; TROPONIN;

EID: 84894553403     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2014.882772     Document Type: Review

References (80)

1. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;128(16): 1810-52
2. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation 2012;125(1): e2-e220
3. Jessup M, Brozena S. Heart failure. N Engl J Med 2003;348(20):2007-18
4. Zile MR, Baicu CF. Biomarkers of diastolic dysfunction and myocardial fibrosis: application to heart failure with a preserved ejection fraction. J Cardiovasc Transl Res 2013;6(4):501-15
5. Mann DL, Barger PM, Burkhoff D. Myocardial recovery and the failing heart: myth, magic, or molecular target? J Am Coll Cardiol 2012;60(24):2465-72
6. Harvey MA. Point-of-care laboratory testing in critical care. Am J Crit Care 1999;8(2): 72-83.quiz 84-75
7. Lee-Lewandrowski E, Lewandrowski K. Perspectives on cost and outcomes for point-of-care testing. Clin Lab Med 2009; 29(3):479-89
8. Asha SE, Chan AC, Walter E, et al. Impact from point-of-care devices on emergency department patient processing times compared with central laboratory testing of blood samples: a randomised controlled trial and cost-effectiveness analysis. Emerg Med J 2013. [Epub ahead of print]
9. Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 2007;115(8):949-52
10. Apple FS, Collinson PO. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem 2012;58(1): 54-61
11. Vanderheyden M, Bartunek J, Goethals M. Brain and other natriuretic peptides: molecular aspects. Eur J Heart Fail 2004; 6(3):261-8
12. Melin J, Rundstrom G, Peterson C, et al. A multiplexed point-of-care assay for C-reactive protein and N-terminal pro-brain natriuretic peptide. Anal Biochem 2011; 409(1):7-13
13. Omland T, Hagve TA. Natriuretic peptides: physiologic and analytic considerations. Heart Fail Clin 2009;5(4):471-87
14. Kelder JC, Cowie MR, McDonagh TA, et al. Quantifying the added value of BNP in suspected heart failure in general practice: an individual patient data meta-analysis. Heart 2011;97(12):959-63
15. Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004;350(7): 647-54
16. Januzzi JL Jr, Chen-Tournoux AA, Moe G. Amino-terminal pro-B-type natriuretic peptide testing for the diagnosis or exclusion of heart failure in patients with acute symptoms. Am J Cardiol 2008;101(3A): 29-38
17. Schmitter D, Cotter G, Voors AA. Clinical use of novel biomarkers in heart failure: towards personalized medicine. Heart Fail Rev 2013. [Epub ahead of print]
18. Ishida J, Suzuki T, Aizawa K, et al. Comparison of analytical performance of two single-step measurement devices of B-type natriuretic Peptide. Int Heart J 2012;53(5):320-3
19. Siebert U, Januzzi JL Jr, Beinfeld MT, et al. Cost-effectiveness of using N-terminal probrain natriuretic peptide to guide the diagnostic assessment and management of dyspneic patients in the emergency department. Am J Cardiol 2006;98(6): 800-5
20. Choudhary R, Gopal D, Kipper BA, et al. Cardiorenal biomarkers in acute heart failure. J Geriatr Cardiol 2012;9(3):292-304
21. Kociol RD, Horton JR, Fonarow GC, et al. Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: data from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) linked to Medicare claims. Circ Heart Fail 2011; 4(5):628-36
22. Kotecha T, Fox K. Investigating suspected heart failure. BMJ 2013;346:f244223
23. Januzzi JL, Troughton R. Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are useful in heart failure management. Circulation 2013;127(4): 500-7.discussion 508
24. Bettencourt P, Azevedo A, Pimenta J, et al. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 2004; 110(15):2168-74
25. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355(9210):1126-30
26. Pfisterer M, Buser P, Rickli H, et al. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA 2009;301(4):383-92
27. Jourdain P, Jondeau G, Funck F, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 2007;49(16):1733-9
28. Porapakkham P, Porapakkham P, Zimmet H, et al. B-type natriuretic peptide-guided heart failure therapy: a meta-analysis. Arch Intern Med 2010; 170(6):507-14
29. Shah AM, Shah SJ, Anand IS, et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the Echocardiographic Study of the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial. Circ Heart Fail 2013. [Epub ahead of print]
30. ClinicalTrials.gov identifier: NCT01685840. Available from: http://clinicaltrials.gov/ct2/ show/NCT01685840?term=Biomarker +guided+therapy&rank=1
31. Effective Health Care Program. Available from: http:// effectivehealthcare.ahrq.gov/ index.cfm/search-for-guides-reviews-andreports/? productid=899&pageaction= displayproduct
32. Ordonez-Llanos J, Collinson PO, Christenson RH. Amino-terminal pro-B-type natriuretic peptide: analytic considerations. Am J Cardiol 2008;101(3A): 9-15
33. de Lemos JA, Hildebrandt P. Amino-terminal pro-B-type natriuretic peptides: testing in general populations. Am J Cardiol 2008;101(3A):16-20
34. Saritas A, Cakir Z, Emet M, et al. Factors affecting the B-type natriuretic peptide levels in stroke patients. Ann Acad Med Singapore 2010;39(5):385-9
35. Valette X, Lemoine S, Allouche S, et al. Effect of lipopolysaccharide, cytokines, and catecholamines on brain natriuretic peptide release from human myocardium. Acta Anaesthesiol Scand 2012;56(7):860-5
36. Pokorna V, Jurkovicova O, Kaluzay J, et al. [Changes in NT-proBNP levels in patients with atrial fibrillation related to heart failure]. Vnitr Lek 2010;56(8):788-94
37. Chang AY, Abdullah SM, Jain T, et al. Associations among androgens, estrogens, and natriuretic peptides in young women: observations from the Dallas Heart Study. J Am Coll Cardiol 2007;49(1): 109-16
38. Reddy P, Samson R. Clinical utility of natriuretic peptides in left ventricular failure. South Med J 2013;106(2):182-7
39. deFilippi CR, de Lemos JA, Christenson RH, et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA 2010;304(22):2494-502
40. Latini R, Masson S. Biomarkers of myocyte injury in heart failure. Heart Fail Clin 2009;5(4):529-36
41. Latini R, Masson S, Anand IS, et al. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 2007;116(11):1242-9
42. Kociol RD, Pang PS, Gheorghiade M, et al. Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. J Am Coll Cardiol 2010; 56(14):1071-8
43. Maisel A, Mueller C, Nowak R, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2010;55(19):2062-76
44. Kakkar R, Lee RT. ST2 and adrenomedullin in heart failure. Heart Fail Clin 2009;5(4):515-27
45. Khan SQ, O'Brien RJ, Struck J, et al. Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. J Am Coll Cardiol 2007;49(14):1525-32
46. Gegenhuber A, Struck J, Dieplinger B, et al. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail 2007;13(1):42-9
47. Boyer B, Hart KW, Sperling MI, et al. Biomarker changes during acute heart failure treatment. Congest Heart Fail 2012; 18(2):91-7
48. Papassotiriou J, Morgenthaler NG, Struck J, et al. Immunoluminometric assay for measurement of the C-terminal endothelin- 1 precursor fragment in human plasma. Clin Chem 2006;52(6):1144-51
49. Drawnel FM, Archer CR, Roderick HL. The role of the paracrine/autocrine mediator endothelin-1 in regulation of cardiac contractility and growth. Br J Pharmacol 2013;168(2):296-317
50. Selvais PL, Robert A, Ahn S, et al. Direct comparison between endothelin-1, N-terminal proatrial natriuretic factor, and brain natriuretic peptide as prognostic markers of survival in congestive heart failure. J Card Fail 2000;6(3):201-7
51. Mueller T, Dieplinger B, Gegenhuber A, et al. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem 2008;54(4):752-6
52. Januzzi JL Jr, Peacock WF, Maisel AS, et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol 2007;50(7):607-13
53. Kempf T, Wollert KC. Growth-differentiation factor-15 in heart failure. Heart Fail Clin 2009;5(4):537-47
54. Kempf T, Eden M, Strelau J, et al. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res 2006;98(3): 351-60
55. Xu J, Kimball TR, Lorenz JN, et al. GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res 2006;98(3): 342-50
56. Baessler A, Strack C, Rousseva E, et al. Growth-differentiation factor-15 improves reclassification for the diagnosis of heart failure with normal ejection fraction in morbid obesity. Eur J Heart Fail 2012; 14(11):1240-8
57. Gupta S, Drazner MH, de Lemos JA. Newer biomarkers in heart failure. Heart Fail Clin 2009;5(4):579-88
58. Sherwi N, Merali S, Wong K. Personalizing biomarker strategies in heart failure with galectin-3. Future Cardiol 2012;8(6):885-94
59. van Kimmenade RR, Januzzi JL Jr, Ellinor PT, et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006; 48(6):1217-24
60. Gullestad L, Ueland T, Kjekshus J, et al. The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Am Heart J 2012;164(6):878-83
61. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347(3):161-7
62. Jungbauer CG, Kaess B, Buchner S, et al. Equal performance of novel N-terminal proBNP (Cardiac proBNP(R)) and established BNP (Triage BNP(R)) point-of-care tests. Biomark Med 2012;6(6): 789-96
63. Diercks DB, Peacock WF, Hollander JE, et al. Diagnostic accuracy of a point-of-care troponin I assay for acute myocardial infarction within 3 hours after presentation in early presenters to the emergency department with chest pain. Am Heart J 2012;163(1):74-80.e74
64. Ro R, Thode HC Jr, Taylor M, et al. Comparison of the diagnostic characteristics of two B-type natriuretic peptide point-of-care devices. J Emerg Med 2011; 41(6):661-7
65. Zaninotto M, Mion MM, Di Serio F, et al. PATHFAST NT-proBNP (N-terminal-pro B type natriuretic peptide): a multicenter evaluation of a new point-of-care assay. Clin Chem Lab Med 2010;48(7):1029-34
66. Breidthardt T, Noveanu M, Cayir S, et al. The use of B-type natriuretic peptide in the management of patients with atrial fibrillation and dyspnea. Int J Cardiol 2009; 136(2):193-9
67. Alehagen U, Janzon M. A clinician's experience of using the Cardiac Reader NT-proBNP point-of-care assay in a clinical setting. Eur J Heart Fail 2008;10(3):260-6
68. Januzzi JL Jr, Camargo CA, Anwaruddin S, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005;95(8):948-54
69. Tomonaga Y, Gutzwiller F, Luscher TF, et al. Diagnostic accuracy of point-of-care testing for acute coronary syndromes, heart failure and thromboembolic events in primary care: a cluster-randomised controlled trial. BMC Fam Pract 2011;12:12
70. Limkakeng AT Jr, Drake W, Mani G, et al. Left ventricular dysfunction screening in hypertensive patients with N-terminal pro-B-type natriuretic peptide and electrocardiogram. Am J Emerg Med 2012; 30(1):214-17
71. Shah K, Terracciano GJ, Jiang K, et al. Comparability of Results between Point-of-Care and Automated Instruments to Measure B-type Natriuretic Peptide. West J Emerg Med 2010;11(1):44-8
72. Ledwidge M, Gallagher J, Conlon C, et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA 2013; 310(1):66-74
73. Burri E, Hochholzer K, Arenja N, et al. B-type natriuretic peptide in the evaluation and management of dyspnoea in primary care. J Intern Med 2012;272(5):504-13
74. Verdu JM, Comin-Colet J, Domingo M, et al. Rapid point-of-care NT-proBNP optimal cut-off point for heart failure diagnosis in primary care. Rev Esp Cardiol (Engl Ed) 2012;65(7):613-19
75. Maisel A, Barnard D, Jaski B, et al. Primary results of the HABIT Trial (heart failure assessment with BNP in the home). J Am Coll Cardiol 2013;61(16):1726-35
76. Loewenstein D, Stake C, Cichon M. Assessment of using fingerstick blood sample with i-STAT point-of-care device for cardiac troponin I assay. Am J Emerg Med 2013;31(8):1236-9
77. Goodacre S, Bradburn M, Fitzgerald P, et al. The RATPAC (Randomised Assessment of Treatment using Panel Assay of Cardiac markers) trial: a randomised controlled trial of point-of-care cardiac markers in the emergency department. Health Technol Assess 2011;15(23):iii-xi, 1-102
78. Friess U, Stark M. Cardiac markers: a clear cause for point-of-care testing. Anal Bioanal Chem 2009;393(5):1453-62
79. Collinson P, Goodacre S, Gaze D, Gray A. Very early diagnosis of chest pain by point-of-care testing: comparison of the diagnostic efficiency of a panel of cardiac biomarkers compared with troponin measurement alone in the RATPAC trial. Heart 2012;98(4):312-18
80. Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J 2006;27(3):330-7